Serotonin 5-HT7 receptor is a biomarker poor prognostic factor and induces proliferation of triple-negative breast cancer cells through FOXM1

Creative Commons License

ÇINAR V., HAMURCU Z., Guler A., Nurdinov N., Ozpolat B.

BREAST CANCER, cilt.29, sa.6, ss.1106-1120, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 29 Sayı: 6
  • Basım Tarihi: 2022
  • Doi Numarası: 10.1007/s12282-022-01391-9
  • Dergi Adı: BREAST CANCER
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.1106-1120
  • Anahtar Kelimeler: FOXM1, Serotonin, 5-HT7 receptor, Metergoline, Breast cancer, REGULATES EXPRESSION, 9-OH-RISPERIDONE, INACTIVATION, RISPERIDONE, APOPTOSIS, INVASION
  • Erciyes Üniversitesi Adresli: Evet

Özet

Background Triple-negative breast cancer (TNBC) is an aggressive type of breast cancer and associated with poor prognosis and shorter survival due to significant genetic heterogeneity, drug resistance and lack of effective targeted therapeutics. Therefore, novel molecular targets and therapeutic strategies are needed to improve patient survival. Serotonin (5-hydroxytryptamine, 5-HT) has been shown to induce growth stimulatory effects in breast cancer. However, the molecular mechanisms by which 5-HT exerts its oncogenic effects in TNBC still are not well understood.